Targeting DNA Damage Response in the Radio(Chemo)therapy of Non-Small Cell Lung Cancer

Lung cancer is the leading cause of cancer death worldwide due to its high incidence and mortality. As the most common lung cancer, non-small cell lung cancer (NSCLC) is a terrible threat to human health. Despite improvements in diagnosis and combined treatments including surgical resection, radioth...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2016-06, Vol.17 (6), p.839-839
Main Authors: Li, Ling, Zhu, Tao, Gao, Yuan-Feng, Zheng, Wei, Wang, Chen-Jing, Xiao, Ling, Huang, Ma-Sha, Yin, Ji-Ye, Zhou, Hong-Hao, Liu, Zhao-Qian
Format: Article
Language:English
Subjects:
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - therapy
Chemoradiotherapy
Chemotherapy
DNA Damage
DNA damage and repair
DNA Repair
Drug Resistance, Neoplasm
Epigenesis, Genetic
epigenetics
genetic polymorphisms
Genotype & phenotype
Humans
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - therapy
MicroRNAs - genetics
non-small cell lung cancer
Polymorphism, Genetic
Radiation therapy
radiotherapy and chemotherapy
resistance
Review
RNA, Long Noncoding
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Lung cancer is the leading cause of cancer death worldwide due to its high incidence and mortality. As the most common lung cancer, non-small cell lung cancer (NSCLC) is a terrible threat to human health. Despite improvements in diagnosis and combined treatments including surgical resection, radiotherapy and chemotherapy, the overall survival for NSCLC patients still remains poor. DNA damage is considered to be the primary cause of lung cancer development and is normally recognized and repaired by the intrinsic DNA damage response machinery. The role of DNA repair pathways in radio(chemo)therapy-resistant cancers has become an area of significant interest in the clinical setting. Meanwhile, some studies have proved that genetic and epigenetic factors can alter the DNA damage response and repair, which results in changes of the radiation and chemotherapy curative effect in NSCLC. In this review, we focus on the effect of genetic polymorphisms and epigenetic factors such as miRNA regulation and lncRNA regulation participating in DNA damage repair in response to radio(chemo)therapy in NSCLC. These may provide novel information on the radio(chemo)therapy of NSCLC based on the individual DNA damage response.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms17060839